- Oral presentation
- Open Access
Structural insights into sGC activation by different activators
BMC Pharmacology volume 11, Article number: O11 (2011)
The soluble guanylyl cyclase (sGC) is a key enzyme involved in the production of the second messenger cGMP. Due its cardiovascular relevance, sGC has been the target of numerous drug discovery efforts leading to the development of many different activators and stimulators with pharmaceutical potential. One of such compounds is the sGC activator Cinaciguat (BAY 58-2667) which is in clinical trials for acute decompensated heart failure.
We present here our latest structure-function studies related to sGC activation by different sGC activators. The activator complex structures reveal an intriguing mode of heme mimicry by these compounds. The observed activation conformational changes center around the αF helix that contains the H105 residue normally held in place by the heme moiety in the absence of the activators.
The structural insights gained from the complex structures could be used for further optimization and development of sGC activators.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
van den Akker, F., Martin, F., Kumar, V. et al. Structural insights into sGC activation by different activators. BMC Pharmacol 11 (Suppl 1), O11 (2011). https://doi.org/10.1186/1471-2210-11-S1-O11
- Discovery Effort
- Change Center
- Guanylyl Cyclase
- Decompensated Heart Failure
- Acute Decompensated Heart Failure